We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $661M
1-Year Est. Return 299.97%
This Fund
S&P 500
This Quarter Est. Return
-22.22%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$326M
AUM Growth
-$419M
Cap. Flow
-$295M
Cap. Flow %
-90.42%
Top 10 Hldgs %
86.05%
Holding
28
New
6
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$21.2M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$10.8M
3
NAMS icon
NewAmsterdam Pharma
NAMS
+$8.02M
4
MRUS
Merus
MRUS
+$3.74M
5
VERA icon
Vera Therapeutics
VERA
+$2.77M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$330M
2
TXG icon
10x Genomics
TXG
+$7.35M
3
ILMN icon
Illumina
ILMN
+$2.68M
4
HLTH
Cue Health Inc. Common Stock
HLTH
+$1.7M
5
WHWK
Whitehawk Therapeutics
WHWK
+$1.23M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WHWK
26
Whitehawk Therapeutics
WHWK
$182M
– –
-526,329
Closed -$1.23M
HLTH
27
DELISTED
Cue Health Inc. Common Stock
HLTH
– –
-8,980,909
Closed -$1.7M
ALPN
28
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-8,317,924
Closed -$330M
1
2

Similar funds

FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $661M AUM 14.84% 1-Year Est. Return
RCG
Regatta Capital Group El Segundo, California $661M AUM 17.85% 1-Year Est. Return
FM
Freemont Management Vaud, Switzerland $661M AUM 60.48% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return

Decheng Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Decheng Capital held 28 positions worth $326M, down 56% from $746M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Decheng Capital withdrew a net $295M in Q2 2024, closing 4 positions and reducing 1 holding. Its most notable exit was Alpine Immune Sciences Inc, an estimated $330M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Decheng Capital opened a new position in Nuvation Bio worth $20.3M.

  • Decheng Capital's largest Q2 2024 buy was Nuvation Bio: 6,950,239 shares worth $20.3M.
  • Decheng Capital added most to Zentalis Pharmaceuticals in Q2 2024, an estimated $10.8M increase.
  • Decheng Capital's biggest Q2 2024 reduction was Illumina, cutting an estimated $2.68M.
  • Decheng Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $330M.
  • Decheng Capital's ten largest holdings make up 86% of its $326M portfolio in Q2 2024.
  • Decheng Capital opened 6 new positions and closed 4 in Q2 2024.
  • Decheng Capital's portfolio value fell 56% quarter-over-quarter to $326M.

Based on Decheng Capital's 13F filing for Q2 2024, filed 14 Aug 2024.